Explore the Agenda
7:15 am Morning Check-in & Coffee
8:15 am Chair’s Opening Remarks
Unpacking 2024’s Successes & Anticipating the Next Challenges to Advance the Future of mRNA-Based Therapeutics & Vaccines
8:30 am CXOs’ Panel Discussion: Unlocking the Next Frontiers of mRNA-Based Vaccines & Therapeutics to Ensure Better Drugs Reach Patients Faster
- What do you think are the top 3 opportunities/near future wins for the mRNA field?
- Given your role in the C-suite, what are the biggest challenges you face on a day-to-day basis and what kind of decisions do you have to make?
- Given your role and affiliation, how do you view the market consolidation and how does it affect your day-to-day and decision making?
- What are your views on the investor climate and partnership strategies or opportunities for collaboration in the mRNA field this year?
9:30 am Clinical Safety & Impact of RNA Cell Therapy in Patients with Myasthenia Gravis
- RNA cell therapy allows transient expression of chimeric antigen receptor in T cells, enabling therapies that do not require lymphodepletion and eliminate risk of cancerous transformation
- Expanding the potential of cell therapies to patients with autoimmunity, where the risk-benefit ratio is more stringent than in oncology
- Sharing our latest data from clinical trials using our autologous BCMA CAR-T product family to treat patients with autoimmunity
10:00 am mRNA Therapeutics: Riding the Next Wave in Biotech
- Eras that define the evolution of biotechnology
- The latest and the greatest in the world of mRNA – the next frontier in biotech
- The bottlenecks in clinical translation and how Resilience is striving to address those challenges
10:30 am Morning Networking Break
Discovery
Unlocking the Power of Next Generation Base Editors & Replicating mRNA for Pushing the Frontiers of mRNA
11:30 am Advancing Next Generation Gene Editing with Beam Therapeutics’ Proprietary Next Generation Base Editor
Personal Assistant, Kivu Bio
- Using mRNA for targeted delivery of a single nucleotide base editor to cure genetic ailments
- Preventing dsDNA breaks for more efficient and predictable gene editing
- Revealing pre-clinical data on ex vivo and in vivo programs targeting diseases such as SCD and alpha-1 anti-trypsin
12:00 pm A Unified Platform for Comprehensive mRNA Characterization
Personal Assistant, Kivu Bio
12:30 pm Enabling Single-Dose, Multivalent Vaccination Against Pathogens of High Consequence Using a Muscle-Localizing NanocarrierFormulated Replicating mRNA
1:00 pm Accessing a Vast Design Space with a Modular High Throughput Platform for RNA Therapeutics & Vaccines
Translation
Clinical Development
CMC
1:10 pm Lunch Networking Break
Discovery
Advancing RNA Drug Development & Design with Next-Generation Discovery Platforms
2:15 pm Introduction to Orna’s Proprietary IRES Discovery & Drug Design Platform for Durable & Sustainable circRNA Expression
2:45 pm Novel Efficient Cap Analogs Development & Application for mRNA Therapeutics
3:15 pm Development of an mRNA Platform to Fight Infectious Disease
Translation
Clinical Development
CMC
3:45 pm Afternoon Networking Break & Poster Session
Discovery
Advancing Next Generation mRNA Drug Development with Optimized mRNA-LNP Platforms to Enable Targeted Delivery
4:30 pm Introducing ZipCode Bio’s Proprietary mRNA Medicine Platform
5:00 pm Shedding Light on dsRNA: Specific & Sensitive Detection Using Bioluminescence
Translation
Clinical Development
CMC